Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

Infection and Immunity

Volumn 67, Issue 7, 1999, Pages 3437-3443

  Coster, Trinka S ^d   Hoge, Charles W ^a   VanDeVerg, Lillian L ^a   Hartman, Antoinette B ^a   Oaks, Edwin V ^a   Venkatesan, Malabi M ^a   Cohen, Dani ^d   Robin, Guy ^d   Fontaine Thompson, Annick ^b,c   Sansonetti, Philippe J ^b   Hale, Thomas L ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b INSERM   (France)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; SHIGELLA VACCINE;

ADULT; ARTICLE; BACTERIAL VIRULENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; GENE DELETION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; SHIGELLA FLEXNERI; SHIGELLOSIS; VACCINATION;

EID: 0032968361     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.7.3437-3443.1999     Document Type: Article

References (37)

1. Barzu, S., A. Fontaine, P. J. Sansonetti, and A. Phalipon. 1996. Induction of local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier. Infect. Immun. 64:1190-1196.
2. Bernardini, M. L., J. Mounier, H. d'Hauteville, M. Coquis-Rondon, and P. J. Sansonetti. 1989. Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin. Proc. Natl. Acad. Sci. USA 86:3867-3871.
3. Cohen, D., S. Ashkenazi, M. S. Green, M. Gdalevich, G. Robin, R. Slepon, M. Yavzori, N. Orr, C. Block, I. Ashkenazi, J. Shemer, D. N. Taylor, T. L. Hale, J. C. Sadoff, D. Pavliakova, R. Schneerson, and J. B. Robbins. 1997. Doubleblind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349:155-159.
4. Cohen, D., N. Orr, G. Robin, R. Slepon, S. Ashkenazi, I. Ashkenazi, and J. Shemer. 1996. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination. Clin. Diagn. Lab. Immunol. 3:451-455.
5. Coster, T. S., et al. Unpublished data.
6. DuPont, H. L., R. B. Hornick, M. J. Snyder, J. P. Libonati, S. B. Formal, and E. J. Gangarosa. 1972. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J. Infect. Dis. 125:12-16.
7. DuPont, H. L., M. M. Levine, R. B. Hornick, and S. B. Formal. 1989. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 159:1126-1128.
8. Ferreccio, C., V. Prado, and A. Ojeda. 1991. Epidemiologic patterns of acute diarrhoea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol. 134:614-627.
9. Fontaine, A., J. Arondel, and P. J. Sansonetti. 1990. Construction and evaluation of live attenuated vaccine strains of Shigella flexneri and Shigella dysenteriae 1. Res. Microbiol. 141:907-912.
10. Goldberg, M., and P. J. Sansonetti. 1994. Shigella subversion of the cytoskeleton: a strategy for epithelial colonization. Infect. Immun. 61:4941-4946.
11. Hale, T. L. 1995. Shigella vaccines, p. 179-203. In D. A. A. Ala'Aldeen and C. E. Hormaeche (ed.), Molecular and clinical aspects of bacterial vaccine development. John Wiley, Ltd., London, England.
12. Hartman, A. B., C. J. Powell, C. L. Schultz, E. V. Oaks, and K. H. Eckels. 1991. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect. Immun. 59:4075-4083.
13. Hartman, A. B., and M. M. Venkatesan. 1998. Construction of a stable attenuated Shigella sonnei ΔvirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infect. Immun. 66:4572-4576.
14. Henry, F. J. 1991. The epidemiologic importance of dysentery in communities. Rev. Infect. Dis. 13(Suppl. 4):S238-S244.
15. Herrington, D. A., L. Van De Verg, S. B. Formal, T. L. Hale, B. D. Tall, S. J. Cruz, E. C. Tramont, and M. M. Levine. 1990. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8:353-357.
16. Karnell, A., A. Li, C. R. Xhao, K. Karlsson, N. B. Minh, and A. A. Lindberg. 1995. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine 13:88-99.
17. Kotloff, K. L., D. A. Herrington, T. L. Hale, J. W. Newland, L. Van De Verg, J. P. Cogan, P. J. Snoy, J. C. Sadoff, S. B. Formal, and M. M. Levine. 1992. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect. Immun. 60:2218-2224.
18. Kotloff, K. L., G. L. Losonsky, J. P. Nataro, S. S. Wasserman, T. L. Hale, D. N. Taylor, J. W. Newland, J. C. Sadoff, S. B. Formal, and M. M. Levine. 1995. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 13:495-502.
19. Kotloff, K. L., J. P. Nataro, G. A. Losonsky, S. S. Wasserman, T. L. Hale, D. N. Taylor, J. C. Sadoff, and L. L. Levine. 1995. Protection against shigellosis following homologous reinfection using a modified volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 13:1488-1494.
20. Kotloff, K. L., F. Noriega, G. A. Losonsky, M. B. Sztein, S. S. Wassserman, J. P. Nataro, and M. M. Levine. 1996. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live, oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect. Immun. 64:4542-4548
21. Li, A., P. D. Cam, D. Islam, N. B. Minh, P. T. Huan, Z. C. Rong, K. Karisson, G. Lindberg, and A. A. Lindberg. 1994. Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124. J. Infect. 28:11-23.
22. Makino, S., C. Sasakawa, K. Kamata, T. Kurata, and M. Yoshikawa. 1986. A genetic determinant required for continuous reinfection of adjacent cells on large plasmid in Shigella flexneri 2a. Cell 46:551-555.
23. Manthan, M. M., and V. I. Manthan. 1991. Morphology of rectal mucosa of patients with shigellosis. Rev. Infect. Dis. 13(Suppl. 4):S314-S318.
24. Nassif, X., M.-C. Mazert, J. Mounier, and P. J. Sansonetti. 1987. Evaluation with an iuc::Tn10 mutant of the role of aerobactin production in the virulence of Shigella flexneri. Infect. Immun. 55:1963-1969.
25. Newland, J. W., T. L. Hale, and S. B. Formal. 1992. Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen. Vaccine 10:766-776.
26. Noriega, F. R., J. Y. Wang, G. Losonsky, D. R. Maneval, D. M. Hone, and M. M. Levine. 1994. Construction and characterization of attenuated ΔaroA ΔvirG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect. Immun. 62:5168-5172.
27. Oaks, E. V., T. L. Hale, and S. B. Formal. 1986. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect. Immun. 53:57-63.
28. Perdomo, J. J., J. M. Cavaillon, M. Huerre, H. Ohayon, P. Gounon, and P. J. Sansonetti. 1994. Acute inflammation causes epithelial invasion and mucosal destruction in experimental shigellosis. J. Exp. Med. 180:1307-1319.
29. Prigent-Delecourt, L., B. Coffin, J. F. Colombel, J. P. Dehennin, J. P. Vaerman, and J. C. Rambaud. 1995. Secretion of immunoglobulins and plasma proteins from the colonic mucosa: an in vitro study in man. Clin. Exp. Immunol. 99:221-225.
30. Rosemans, C., M. L. Bennish, and T. Wierzba. 1988. Diagnosis and management of dysentery by community health workers. Lancet 2:552-555.
31. Sack, R. B., M. Rahman, M. Yunus, and E. H. Khan. 1997. Antimicrobial resistance in organisms causing diarrheal disease. Clin. Infect. Dis. 24(Suppl. 1):S102-S105.
32. Sansonetti, P. J., J. Arondel, A. Fontaine, H. d'Hauteville, and M. L. Bernardini. 1991. ompB (osmo-regulation) and icsA (cell-to-cell spread) mutants of S. flexneri: vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine 9:415-421.
33. Sansonetti, P. J., and J. Arondel. 1989. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 7:443-450.
34. Teska, J. D., T. Coster, W. R. Byrne, J. R. Colbert, D. Taylor, M. Venkatesan, and T. L. Hale. J. Lab. Clin. Med., in press.
35. Van De Verg, L., D. A. Herrington, J. R. Murphy, S. S. Wasserman, S. B. Formal, and M. M. Levine. 1990. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect. Immun. 58:2002-2004.
36. Vasselon, T., J. Mounier, R. Hellio, and P. J. Sansonetti. 1992. Movement along actin filaments of the perijunctional area and de novo polymerization of cellular actin are required for Shigella flexneri colonization of epithelial Caco-2 cell monolayers. Infect. Immun. 60:1031-1040.
37. Wilson, R., R. A. Feldman, and J. Davis. 1981. Family illness associated with Shigella infection: the interrelationship of age of the index patient and the age of household members in acquisition of illness. J. Infect. Dis. 143:130-132.